Omeros hit hard on knee surgery drug failure

Blaming "confounding factors," Seattle-based Omeros ($OMER) said its Phase III trial of knee surgery drug OMS103HP didn't meet any of the endpoints specified for the study. The drug is designed to improve joint motion and reduce pain in people who've undergone arthroscopic surgery to fix a major ligament in the knee. Omeros didn't elaborate on what factors led to the trial outcome.

"Given the strength of the data from previous clinical studies of OMS103HP, we are obviously disappointed and surprised by the outcome," stated CEO Gregory Demopulos. "As we learn more from our data analysis, we will provide additional information on our plans for OMS103HP." He emphasized that the study outcome doesn't mean the drug isn't effective, and shouldn't interfere with a planned Phase III trial of OMS103HP for surgery of the meniscus.

- here's Omeros' release
- read more from the AP

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.